Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD21 CRISPR/Cas9 KO Plasmid (m): sc-419789
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD21 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD21 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD21 Antibody (A-3): sc-13135
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD21 CRISPR/Cas9 KO Plasmid (m) | sc-419789 | 20 µg | $397.00 |
Overview
Cr2 encodes CD21 (complement receptor 2), a surface receptor highly expressed on B cells and follicular dendritic cells that binds complement fragments such as C3d to lower the threshold for B cell receptor activation and promote antigen retention. CD21 functions within the CD19–CD81 co-receptor complex to amplify signaling through pathways including PI3K–AKT and MAPK, supporting germinal center responses, class-switch recombination, and memory B cell formation. In mouse immunology, Cr2/CD21 is central to complement-driven humoral immunity and immune complex handling, making it relevant for studies of dysregulated B cell activation, autoantibody generation, and altered host responses to pathogens.
CD21 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cr2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cr2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cr2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD21 protein expression.
This CRISPR knockout system enables efficient generation of Cr2-deficient cell models for investigation of CD21 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cr2 exon(s) critical for CD21 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cr2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD21 CRISPR/Cas9 KO Plasmid (m) and CD21 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cr2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD21 HDR Plasmid (m) and CD21 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cr2 homology arms to support homology-directed repair at defined Cr2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.